NCT02933502

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Accepted

Summary

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Detailed description

* Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. * Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	DSXS topical product	treatment daily for 28 days

Timeline

• Start date: 2016-07-11
• Primary completion: 2017-09-20
• Completion: 2018-01-02
• First posted: 2016-10-14
• Last updated: 2018-12-10
• Results posted: 2018-12-10

Locations

1 site across 1 country: United States